# Phase 1/2 Study of BHB810 in Advanced Gastric and GEJ Adenocarcinoma

Source: https://onco.cc/trials/nct07529808/  
OnCo record `nct07529808` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of BHB810 in gastric & gastro-oesophageal junction cancer, oesophageal cancer, colorectal cancer and pancreatic ductal adenocarcinoma, run by BigHat Biosciences, Inc., now recruiting.

## Summary

Phase 1/2 Study of BHB810 in Advanced Gastric and GEJ Adenocarcinoma is a phase 1/2 interventional study registered as NCT07529808 by BigHat Biosciences, Inc., with 164 participants planned, started 2026-07 and due to reach its primary completion in 2028-12. Interventions recorded: BHB810.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07529808
- Phase: 1/2
- Setting: Phase 1/2, Open-Label, Multicenter, Dose Escalation and Expansion Study of BHB810 in Participants With Advanced Gastric and Gastroesophageal Junction Adenocarcinoma
- Sponsor: BigHat Biosciences, Inc.
- Enrolled: 164

## Sources

- ClinicalTrials.gov NCT07529808: https://clinicaltrials.gov/study/NCT07529808

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/), [Oesophageal cancer](https://onco.cc/cancers/esophageal/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- companies: [BigHat Biosciences](https://onco.cc/companies/bighat-biosciences/)

---
JSON: https://onco.cc/api/v1/entities/nct07529808.json